Tumor growth rate in well-differentiated G1-3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Implications for clinical trials

#3283

Introduction: Drug development in G1-3 GEP-NETs is hampered by heterogeneous tumor biology and the cytostatic nature of most active agents. Optimal care of G3NETs is ill-defined, as recent phase 3 studies have not accounted for this group. Tumor growth rate (TGR) allows dynamic evaluation of growth and has prognostic value in G1-2; little is known about TGR in G3.

Aim(s): We characterized pre-treatment (pre-tx) TGR (TGR0), Ki67 index and heterogeneity across G1-3.

Materials and methods: Retrospective review of untreated patients (pts) with advanced G1-3 GEP-NET, baseline imaging, and UCSF pathology review of pre-tx Ki67. TGR0 defined as % change in RECIST-measurable metastatic target lesion size per month [%/m] using 2 pre-tx contrast-enhanced CT/MRI.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Wang S, Whitman J, Paciorek A, Le B, Zhang L,

Keywords: GEP-NET, tumor growth rate, Ki67,